News Website

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer | AZN Stock News - GuruFocus

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer | AZN Stock News GuruFocus

Published: June 9, 2025, 12:18 p.m.

Read Full Article

Biomarker-Driven Decisions: Insights on Selecting Treatments in Advanced and Recurrent Endometrial Cance - OncLive

Biomarker-Driven Decisions: Insights on Selecting Treatments in Advanced and Recurrent Endometrial Cance OncLive

Published: May 19, 2025, 12:21 p.m.

Read Full Article

Recurrent Abdominal Pain Caused by a Parasitic Leiomyoma Containing Endometrial Cells Following Laparoscopic Hysterectomy - Cureus

Recurrent Abdominal Pain Caused by a Parasitic Leiomyoma Containing Endometrial Cells Following Laparoscopic Hysterectomy Cureus

Published: May 19, 2025, 11:07 a.m.

Read Full Article

VIDEO: Puxitatug samrotecan shows promise for patients with recurrent endometrial cancer - Healio

VIDEO: Puxitatug samrotecan shows promise for patients with recurrent endometrial cancer Healio

Published: May 14, 2025, 8:04 p.m.

Read Full Article

Dostarlimab/Chemo Earns Expanded Canadian Approval in Primary Advanced, First Recurrent Endometrial Cancer - OncLive

Dostarlimab/Chemo Earns Expanded Canadian Approval in Primary Advanced, First Recurrent Endometrial Cancer OncLive

Published: April 18, 2025, 3:54 p.m.

Read Full Article

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - BioSpace

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to …

Published: April 18, 2025, 5:25 a.m.

Read Full Article

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - The Malaysian Reserve

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to …

Published: April 18, 2025, 12:16 a.m.

Read Full Article

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - Yahoo Finance

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to …

Published: April 17, 2025, 5:15 p.m.

Read Full Article

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - Newswire.ca

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to …

Published: April 17, 2025, 5:15 p.m.

Read Full Article

Real-World Use of ICI in Advanced or Recurrent Endometrial Cancer - OncLive

Real-World Use of ICI in Advanced or Recurrent Endometrial Cancer OncLive

Published: April 14, 2025, 2:41 p.m.

Read Full Article

Latest Articles

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer | AZN Stock News - GuruFocus

Biomarker-Driven Decisions: Insights on Selecting Treatments in Advanced and Recurrent Endometrial Cance - OncLive

Recurrent Abdominal Pain Caused by a Parasitic Leiomyoma Containing Endometrial Cells Following Laparoscopic Hysterectomy - Cureus

VIDEO: Puxitatug samrotecan shows promise for patients with recurrent endometrial cancer - Healio

Dostarlimab/Chemo Earns Expanded Canadian Approval in Primary Advanced, First Recurrent Endometrial Cancer - OncLive

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - BioSpace

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - The Malaysian Reserve

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - Yahoo Finance

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - Newswire.ca

Real-World Use of ICI in Advanced or Recurrent Endometrial Cancer - OncLive

Subscribe to Our Newsletter